Wells Fargo’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

Wells Fargo’s Portfolio KRBP Stock Details KRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6	Closed	-$16	–	7815
2023 Q2	$16	Buy	6 +2	+50%	+$7	﹤0.01%	7359
2023 Q1	$15	Buy	4 +1	+33%	+$5	﹤0.01%	7443
2022 Q4	$14	Hold	3	–	–	﹤0.01%	7347
2022 Q3	$0	Buy	3 +2	+200%	+$23	﹤0.01%	7780
2022 Q2	$0	Hold	1	–	–	﹤0.01%	7877
2022 Q1	$0	Hold	1	–	–	﹤0.01%	8190
2021 Q4	$0	Hold	1	–	–	﹤0.01%	8118
2021 Q3	$0	Buy	+1	New	+$103	﹤0.01%	7788
2021 Q2	–	Hold	0	–	–	–	7717
2021 Q1	–	Hold	0	–	–	–	7623
2020 Q4	–	Hold	0	–	–	–	7265

Wells Fargo's KRBP Position: Q3 2023 in Review

Wells Fargo sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q3 2023, closing a stake of 6 shares — an estimated $16 sold.

Wells Fargo first reported a position in KRBP in Q3 2021 and held it in 8 quarters. The position peaked at $16 in Q2 2023. 0 funds tracked by Wall St. Rank hold KRBP as of Q3 2023.

Wells Fargo reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Wells Fargo sold 6 Kiromic BioPharma, Inc. Common Stock shares in Q3 2023, an estimated $16.
Wells Fargo first reported a position in Kiromic BioPharma, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
Wells Fargo's Kiromic BioPharma, Inc. Common Stock position peaked at $16 in Q2 2023.
0 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q3 2023.

Based on Wells Fargo's 13F filing for Q3 2023, filed 13 Nov 2023.